Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Dova Pharmaceuticals Stock Jumped Higher Today

By Brian Orelli, PhD - Jun 27, 2019 at 2:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker's Doptelet therapy just received an expanded approval.

What happened

Shares of Dova Pharmaceuticals ( DOVA ) were up 18.5% at 1:33 p.m. EDT today after the biotech, which is focused on thrombocytopenia (low blood-platelet count), announced that the FDA had expanded the approval for Doptelet to include the treatment of that condition in adults with a blood disease called chronic immune thrombocytopenia. This is a second-line approval, meaning patients need to have had an insufficient response to a previous treatment.

So what

Doptelet was already approved in the U.S. to treat thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a procedure. Just two days ago, Dova got the drug approved in Europe for the same liver disease indication.

Dova is getting help from Bausch Health Companies( BHC 1.15% ) Salix Pharmaceuticals to sell Doptelet to U.S.-based surgeons looking to use the drug to treat patients with chronic liver disease. That should free up Dova to focus on the launch for immune thrombocytopenia, which is a bigger opportunity, but a disease where Dova will have to go against established drugs, such as Amgen's ( AMGN 0.63% ) Nplate and GlaxoSmithKline's ( GSK -0.53% ) Promacta.

Doctor with arm on patient's shoulder

Image source: Getty Images.

Now what

Today's FDA approval is certainly good news, but investors should have patience in their expectations for Doptelet's launch in immune thrombocytopenia. Small biotechs often take awhile to get up to full speed, especially when they have to compete with big pharma.

If the immune thrombocytopenia opportunity doesn't work out as expected, Dova has one more shot to expand sales of Doptelet into chemotherapy-induced thrombocytopenia. Data from a phase 3 study for that version of the disease will be available in first half of 2020.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dova Pharmaceuticals, Inc. Stock Quote
Dova Pharmaceuticals, Inc.
Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
$23.73 (1.15%) $0.27
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
$41.25 (-0.53%) $0.22
Amgen Inc. Stock Quote
Amgen Inc.
$202.44 (0.63%) $1.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.